Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients on the basis of cannabis use alone.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments remain efficacious in the substantial subset of PTSD+SUD patients who use cannabis, informing treatment selection and expectations in this high-risk, understudied population. The findings clarify whether cannabis use represents a contraindication to standard PTSD interventions or a manageable comorbidity, which has significant implications for treatment planning and resource allocation in integrated behavioral health settings. Understanding differential treatment response in cannabis-using versus non-using patients with co-occurring PTSD and SUD can guide clinicians in optimizing intervention strategies and setting realistic outcomes for this complex patient population.
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
? This meta-analysis examining trauma-focused treatment outcomes in patients with co-occurring PTSD and substance use disorders who also use cannabis addresses a clinically relevant question, though several limitations warrant careful interpretation. The analysis draws from Project Harmony’s substantial dataset, yet the specific subset examining cannabis use appears limited to four RCTs, which reduces statistical power and generalizability compared to the full meta-analysis cohort. Key confounders remain inadequately controlled, including cannabis use frequency and pattern, concurrent medications, polysubstance use profiles, and whether patients used cannabis as self-medication versus independent use disorder, all of which could substantially influence treatment response independent of the intervention itself. From a practical standpoint, this evidence suggests that cannabis use alone should not automatically disqualify patients from evidence-based trauma-focused therapies like prolonged exposure or cognitive processing therapy, though clinicians should remain vigilant for potential interactions between cannabinoids and psychological processing during treatment, and may need to adjust pacing or incorporate substance-specific motivational interventions for those
| |
Have thoughts on this? Share it:
